GleamWall
中文EN

BLLN BillionToOne, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2070849 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY71.9%
TTM net income YoY593.9%
TTM EPS YoY183.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin71.4%
Operating margin10.2%
Net margin11.3%
FCF margin7.8%
EBITDA margin11.9%

Returns

ROE30.2%
ROA9.1%
ROIC (approx.)—
Asset turnover0.80x

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.16x
Current ratio11.25x
Interest coverage1,655.26x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio0.3%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$122.98M$109.45M$108.39M$96.05M$83.52M$66.57M$58.96M$45.08M
Cost of revenue$35.84M$32.34M$29.29M$27.45M$25.11M$23.11M$20.99M$19.36M
Gross profit$87.14M$77.11M$79.10M$68.60M$58.42M$43.47M$37.97M$25.72M
R&D expense$20.22M$17.32M$14.69M$14.25M$12.95M$11.75M$10.43M$11.00M
SG&A expense$55.91M$54.29M$46.57M$44.02M$35.83M$33.34M$29.86M$26.41M
Operating income$11.02M$5.50M$17.83M$10.33M$9.63M-$1.63M-$2.31M-$11.69M
Interest expense$6,000$8,000$10,000$3,000$20,000$32,000$40,000$47,000
Pretax income$17.39M$7.52M$18.51M$6.30M$5.58M-$232,000-$3.89M-$11.45M
Income tax$1,300-$536,000$539,000$320,000-$129,000$14,500$100,000$24,000
Net income$17.39M$8.05M$17.97M$5.98M$5.71M-$246,000-$3.99M-$11.48M
EBITDA$13.00M$7.33M$19.57M$12.00M$11.32M$120,000-$522,000-$9.93M
EPS (basic)0.370.170.39—0.14-0.02-0.39—
EPS (diluted)0.320.150.34—0.10-0.02-0.39—
Weighted avg. shares (diluted)53.73M54.46M53.03M—15.57M10.38M10.31M—
Balance sheet
Cash & equivalents$561.51M$548.63M$537.45M$495.98M$195.15M$188.96M$191.60M$191.48M
Receivables$88.28M$74.89M$61.30M$41.62M$34.65M——$24.71M
Inventory$21.89M$21.14M$19.22M$17.55M$17.39M——$8.73M
Current assets$682.09M$651.38M$624.14M$560.56M$251.72M——$227.82M
PP&E, net$26.78M$24.93M$22.28M$20.36M$18.67M——$17.11M
Total assets$760.49M$729.70M$700.73M$632.65M$327.52M——$302.06M
Current liabilities$60.64M$55.73M$57.16M$47.96M$40.78M——$28.39M
Short-term debt———$0———$0
Long-term debt$88.98M$91.03M$90.00M$57.23M$54.99M——$51.48M
Total debt$88.98M$91.03M$90.00M$57.23M$54.99M——$51.48M
Total liabilities$193.94M$192.89M$195.11M$152.55M$147.62M——$134.31M
Shareholders' equity$566.55M$536.81M$505.62M$480.11M-$239.51M-$250.25M-$252.91M-$251.66M
Net debt-$472.53M-$457.60M-$447.44M-$438.75M-$140.17M——-$140.00M
Shares outstanding————11.18M——10.93M
Cash flow statement
Operating cash flow$12.55M$9.14M$15.43M$10.79M$10.00M$1.18M$2.62M-$8.42M
Capital expenditure$3.95M$4.05M$4.47M$1.54M$2.12M$2.87M$2.35M$2.07M
Free cash flow$8.60M$5.09M$10.96M$9.26M$7.87M-$1.69M$278,000-$10.50M
Investing cash flow-$3.95M-$4.05M-$4.47M-$1.58M-$2.12M-$2.87M-$2.35M-$2.10M
Financing cash flow$4.28M$6.09M$30.52M$291.61M-$1.68M-$949,000-$156,000-$288,000
Depreciation & amortization$1.97M$1.83M$1.74M$1.67M$1.69M$1.75M$1.79M$1.76M
Stock-based compensation$9.70M$8.22M$6.51M$6.33M$4.47M$2.73M$2.37M$2.31M
Share buybacks———$0———$0

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.